Black Diamond Therapeutics, Inc.
BDTX
$2.58
-$0.11-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.66% | -17.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.20% | -13.25% | |||
| Operating Income | 18.20% | -124.61% | |||
| Income Before Tax | 19.53% | -118.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.53% | -118.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.53% | -118.68% | |||
| EBIT | 18.20% | -124.61% | |||
| EBITDA | 18.31% | -124.41% | |||
| EPS Basic | 19.69% | -118.63% | |||
| Normalized Basic EPS | 19.71% | -118.77% | |||
| EPS Diluted | 21.05% | -119.39% | |||
| Normalized Diluted EPS | 19.71% | -119.11% | |||
| Average Basic Shares Outstanding | 0.22% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.22% | -1.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||